Nightly Sleep Apnea Pill Fast-Tracked for Approval After Latest Trial Success

AD109, a nightly oral drug for obstructive sleep apnea, significantly reduced apnea severity in a 26-week phase 3 trial of 646 patients.

The study focused on people who could not or would not use CPAP, the current standard treatment.

Based on the results, the FDA has fast-tracked review of the drug, with a possible approval decision in 2027.

If approved, AD109 could offer a more convenient alternative for millions of patients who struggle with CPAP adherence.